SpringerProtocols: Abstract: Enzyme-Prodrug Systems: Carboxylesterase/CPT-11

Enzyme-Prodrug Systems: Carboxylesterase/CPT-11

By: Mary K. Danks², Philip M. Potter²

Abstract

Full Text

Download PDF (949K)

The development of enzyme-prodrug approaches for targeted treatment of human tumors has gained momentum in the last decade, especially with the advent of antibodies, viral vectors, and nonviral delivery systems that might be suitable for use in vivo. However, relatively few novel enzyme-prodrug combinations have been developed for use with these vectors. Because tumors differ in their intrinsic sensitivity to specific classes of chemotherapeutic agents, it is unlikely that any single enzyme-prodrug combination will be effective for all types of cancer. The design of additional vectors, enzymes, and prodrugs needs to be pursued. This section discusses the use of carboxylesterases (CEs) to activate the prodrug CPT-11 irinotecan, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin.

Affiliation(s): (2) Department of Molecular Pharmacology, St. Jude Children’s Research Hospital, Memphis, TN

Book Title: Suicide Gene Therapy: Methods and Reviews

Series: Methods in Molecular Medicine | Volume: 90 | Pub. Date: Nov-04-2003 | Page Range: 247-262 | DOI: 10.1385/1-59259-429-8:247

Subject: Genetics/Genomics

References

Download References

1.	Tanizawa, A., Fujimori, A., Fujimori, Y., and Pommier, Y. (1994) Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J. Natl. Cancer Inst. 86, 836–842.

2.	Houghton, P. J., Cheshire, P. J., Hallman, J. D., 2nd, et al. (1995) Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother. Pharmacol. 36, 393–403.

3.	Houghton, J. A., Cheshire, P. J., Hallman, J. A., et al. (1996) Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma. Clin. Cancer Res. 2, 107–118.

4.	Bissery, M. C., Vrignaud, P., Lavelle, F., and Chabot, G. G. (1996) Preclinical antitumor activity and pharmacokinetics of irinotecan (CPT-11) in tumor-bearing mice. Ann. NY Acad. Sci. 803, 173–180.

5.	Bissery, M. C., Vrignaud, P., Lavelle, F., and Chabot, G. G. (1996) Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. Anticancer Drugs 7, 437–460.

6.	Thompson, J., Zamboni, W. C., Cheshire, P. J., et al. (1997) Efficacy of oral irinotecan against neuroblastoma xenografts. Anticancer Drugs 8, 313–322.

7.	Thompson, J., Zamboni, W. C., Cheshire, P. J., et al. (1997) Efficacy of systemic administration of irinotecan against neuroblastoma xenografts. Clin. Cancer Res. 3, 423–431.

8.	Baker, L., Khan, R., Lynch, T., et al. (1997) Phase II study of irinotecan (CPT-11) in advanced non-small cell lung cancer (NSCLC). Proc. Annu. Meet. Am. Soc. Clin. Oncol. 16, A1658 (abstract).

9.	Escudier, B., Fizazi, K., Rolland, F., et al. (1997) Phase II study of irinotecan (CPT 11) in pretreated (A) or not pretreated (B) patients (pts) with advanced renal cell carcinoma. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 16, A1188 (abstract).

10.	Furman, W. L., Stewart, C. F., Poquette, C. A., et al. (1999) Direct translation of a protracted irinotecan schedule from a xenograft model to a Phase I trial in children. J. Clin. Oncol. 17, 1815–1824.

11.	Rivory, L. P., Haaz, M.-C., Canal, P., Lokiec, F., Armand, J.-P., and Robert, J. (1997) Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in Phase I/II trials. Clin. Cancer Res. 3, 1261–1266.

12.	Rivory, L. P., Bowles, M. R., Robert, J., and Pond, S. M. (1996) Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Biochem. Pharmacol. 52, 1103–1111.

13.	Slatter, J. G., Su, P., Sams, J. P., Schaaf, L. J., and Wienkers, L. C. (1997) Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. Drug Metab. Dispos. 25, 1157–1164.

14.	Humerickhouse, R., Lohrbach, K., Li, L., Bosron, W., and Dolan, M. (2000) Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res. 60, 1189–1192.

15.	Khanna, R., Morton, C. L., Danks, M. K., and Potter, P. M. (2000) Proficient metabolism of CPT-11 by a human intestinal carboxylesterase. Cancer Res. 60, 4725–4728.

16.	Morton, C. L., Wadkins, R. M., Danks, M. K., and Potter, P. M. (1999) CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase. Cancer Res. 59, 1458–1463.

17.	Petit, R. G., Rothenberg, M. L., Mitchell, E. P., Compton, L. D., and Miller, L. L. (1997) Cholinergic symptoms following CPT-11 infusion in a phase II multicenter trial of 250 mg/m² irinotecan (CRT-11) given every two weeks. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 16, A953 (abstract).

18.	Potter, P. M., Pawlik, C. A., Morton, C. L., Naeve, C. W., and Danks, M. K. (1998) Isolation and partial characterization of a cDNA encoding a rabbit liver carboxylesterase that activates the prodrug Irinotecan (CPT-11). Cancer Res. 52, 2646–2651.

19.	Potter, P. M., Wolverton, J. S., Morton, C. L., Whipple, D. O., and Danks, M. K. (1998) In situ subcellular localization of epitope tagged human and rabbit carboxylesterases. Cytometry 32, 223–232.

20.	Potter, P. M., Wolverton, J. S., Morton, C. L., Wierdl, M., and Danks, M. K. (1998) Cellular localization domains of a rabbit and a human carboxylesterase: influence on irinotecan (CPT-11) metabolism by the rabbit enzyme. Cancer Res. 58, 3627–3632.

21.	Wadkins, R. M., Morton, C. L., Weeks, J. K., et al. (2001) Structural constraints affect the metabolism of CPT-11 by esterases. Mol. Pharmacol. 60, 355–362.

22.	Munger, J. S., Shi, G. P., Mark, E. A., Chin, D. T., Gerard, C., and Chapman, H. A. (1991) A serine esterase released by human alveolar macrophages is closely related to liver microsomal carboxylesterases. J. Biol. Chem. 266, 18,832–18,838.

23.	Danks, M. K., Morton, C. L., Krull, E. J., et al. (1999) Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy. Clin. Cancer Res. 5, 917–924.

24.	Morton, C. L., Wierdl, M., Oliver, L., et al. (2000) Activation of CPT-11 in mice: Identification and analysis of a highly effective plasma esterase. Cancer Res. 60, 4206–4210.

25.	Schwer, H., Langmann, T., Daig, R., Becker, A., Aslanidis, C., and Schmitz, G. (1997) Molecular cloning and characterization of a novel putative carboxylesterase, present in human intestine and liver. Biochem. Biophys. Res. Commun. 233, 117–120.

26.	Sussman, J. L., Harel, M., Frolow, F., et al. (1991) Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science 253, 872–879.

27.	Sali, A. and Blundell, T. J. (1993) Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 234, 779–815.

28.	Danks, M. K., Morton, C. L., Pawlik, C. A., and Potter, P. M. (1998) Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11. Cancer Res. 58, 20–22.

29.	Rill, D., Santana, V., Roberts, W., et al. (1994) Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 84, 380–383.

30.	Wagner, L. M., Guichard S. M., Burger, R. Z., et al. (2002) Efficacy and toxicity of a virus-directed enzyme prodrug therapy purging method: practical assessment and application to bone marrow samples from neuroblastoma patients. Cancer Res. 62, 5001–5007.

31.	Meck, M., Wierdl, M., Wagner, L., et al. (2001) A VDEPT approach to purging neuroblastoma cells from hematopoeitic cells using adenovirus encoding rabbit carboxylesterase and CPT-11. Cancer Res., 61, 5083–5089.

32.	Iyengar, R. V., Pawlik, C. A., Krull, E. J., et al. (2001) Use of a modified ornithine decarboxylase promoter to achieve efficient c-MYC or N-MYC-regulated protein expression. Cancer Res. 61, 3045–3052.

33.	Blackwell, T. K., Kretzner, L., Blackwood, E. M., Eisenman, R. N., and Weintraub, H. (1990) Sequence-specific DNA binding by the c-Myc protein. Science 250, 1149–1151.

34.	Blackwood, E. M. and Eisenman, R. N. (1991) Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 251, 1211–1217.

35.	Kretzner, L., Blackwood, E. M., and Eisenman, R. N. (1992) Myc and Max proteins possess distinct transcriptional activities. Nature 359, 426–429.

36.	Bello-Fernandez, C. and Cleveland, J. L. (1992) c-myc transactivates the ornithine decarboxylase gene. Curr. Topics Microbiol. Immunol. 182, 445–452.

37.	Bello-Fernandez, C., Packham, G., and Cleveland, J. L. (1993) The ornithine decarboxylase gene is a transcriptional target of c-Myc. Proc. Natl. Acad. Sci. USA 90, 7804–7808.

Comments (Loading...)

Post comment/View all comments